FesariusTherapeutics Raises $20M in Series A Funding

The round also saw participation from Johnson and Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development’s NY Ventures, and the American Society of Plastic Surgeons (ASPS).

The company plans to use the funding to expand its operations, and accelerate research and development efforts.

The financing marks an important milestone for Fesarius, validating its technology through clinical use and strengthening its commercial momentum across US hospital systems. The funding positions the company for its next stage of growth.

With the new capital Fesarius plans to expand its commercial operation's by increasing its direct sales team and broadening market coverage across the United States. The company will also work toward obtaining Breakthrough Device Designation and expanding reimbursement opportunities.

In addition, Fesarius will advance the clinical trial of its OneStep procedure, which combines the placement of DermiSphere™ and a skin graft in a single surgery. The company plans to pursue a future label expansion for this use of the device.

If approved, the OneStep procedure could eliminate the second surgery required under the current standard of care, potentially reducing recovery time, patient discomfort and overall healthcare costs.

The U.S. dermal regeneration market, valued at approximately $1.6 billion, has seen little innovation over the past three decades. DermiSphere™ is the first human dermal regenerative template (hDRT) of its kind, designed with a unique dual-density collagen structure that promotes faster tissue growth and blood vessel formation. By supporting the body's natural healing process, DermiSphere™ aims to improve wound healing and tissue regeneration outcomes for patients.

"We are excited to support Fesarius vision to revolutionize deep wound care and help improve outcomes for millions of patients who require skin grafts. DermiSphere™ is already making a difference for patients. We believe Fesarius is positioned to redefine the category. "Laura Lande-Diner, Managing Partner, Jefferson Life Sciences.

"New York is building one of the nation's most dynamic life sciences ecosystems, and companies like Fesarius are exactly why. DermiSphere™ is the kind of innovation we want developed and scaled here, with the potential to dramatically improve outcomes for patients while creating high-quality jobs and economic opportunity across the state. Through NY Ventures, we're proud to invest in New York innovators defining the future of medicine." - Jennifer Tegan, Managing Director, New York Ventures, Empire State Development.

"This inaugural investment in Fesarius marks a new chapter for ASPS Ventures, one where we move from advocates to active partners in advancing technologies developed by our members. We are proud to play a role in helping to bring this technology to the patients who need it most." - Michael Costelloe, Executive Vice President of the American Society of Plastic Surgeons and CEO of ASPS Ventures, LLC.

Read More:TensorWave Raises $350M in Series B Funding at $1.55B Valuation

"DermiSphere™ is creating a new frontier in dermal repair by fundamentally changing how surgeons treat seriously destructive skin loss. Patients are experiencing promising outcomes already, and this financing accelerates our clinical programs, expands our commercial reach, and ensures that every patient can access the truly remarkable outcomes we are seeing with DermiSphere™hDRT." - Tom Roueche, President and CEO, FesariusTherapeutics.

About FesariusTherapeutics

Founded in 2015 by Jason Spector, Fesarius Therapeutics is a medical technology company focused on advancing wound healing and dermal repair. It's flagship product, DermiSphere™, is a hydrogel based dermal regeneration template designed to support tissue growth, cellular integration and blood vessel formation through its patented dual density collagen structure. DermiSphere™ has received FDA 510(k) clearance for wound management and is already being used across multiple hospital systems in the United States.

Read More:SonoThera Raises $125M in Series B Funding Led by Vida Ventures